AbbVie: Macular Degeneration trials

The registry lists 21 Macular Degeneration studies with AbbVie as lead sponsor. 2 are open to participants now and 13 have results posted.

Phase 1 5Phase 2 15Phase 3 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular DegenerationRecruitingNCT07160179Phase 1/2
• Long-term Follow-Up Study of RGX-314 and Fellow Eye SubstudyEnrolling by invitationNCT03999801Phase 2
• A Study to Evaluate Abicipar Pegol for Safety and Treatment Effect in Participants With Neovascular Age-related Macular Degeneration (AMD)CompletedNCT03539549Phase 2Results posted
• A Safety and Efficacy Study of Abicipar Pegol in Participants With Neovascular Age-related Macular DegenerationCompletedNCT02462928Phase 3Results posted
• Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular DegenerationCompletedNCT02462486Phase 3Results posted
• A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular DegenerationCompletedNCT02181517Phase 2Results posted
• A Study of Abicipar Pegol in Japanese Patients With Neovascular Age-related Macular DegenerationCompletedNCT02181504Phase 2Results posted
• A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular DegenerationTerminatedNCT02087085Phase 2Results posted
• Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD)CompletedNCT01397409Phase 2Results posted
• Safety and Efficacy of Dexamethasone as Adjunctive Therapy to Ranibizumab in Subjects With Choroidal Neovascularization and Age-Related Macular DegenerationTerminatedNCT01122511Phase 2Results posted
• Study of MP0112 Intravitreal Injection in Patients With Wet Age Related Macular DegenerationTerminatedNCT01086761Phase 1Results posted
• Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) in Subjects With Wet Age-Related Macular Degeneration (AMD)CompletedNCT00775411Phase 2Results posted
• Safety and Efficacy of Brimonidine Intravitreal Implant in Patients With Geographic Atrophy Due to Age-related Macular Degeneration (AMD)CompletedNCT00658619Phase 2Results posted
• Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD)CompletedNCT00511706Phase 2Results posted
• A Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related Macular DegenerationTerminatedNCT00395057Phase 2Results posted
• Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMDActive, not recruitingNCT05407636Phase 3
• RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD)CompletedNCT04832724Phase 2
• Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMDActive, not recruitingNCT04704921Phase 2/3
• Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Japanese Patients With Neovascular AMDCompletedNCT03335852Phase 1
• Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Patients With Neovascular AMDCompletedNCT02859766Phase 1
• A Dose Escalation Trial of an Intravitreal Injection of Sirna-027 in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)CompletedNCT00363714Phase 1/2